Tang Capital reports 0.1% stake in Adicet Bio
Adicet Bio, Inc. shareholder Tang Capital Management and affiliated entities report beneficial ownership of 6,158 common shares, representing about 0.1% of the company’s outstanding common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Adicet Bio, Inc. shareholder Tang Capital Management and affiliated entities report beneficial ownership of 6,158 common shares, representing about 0.1% of the company’s outstanding common stock. The filing attributes shared voting and dispositive power over these shares to Tang Capital Management, Kevin Tang, and Tang Capital Partners International, LP.
The percentage is based on 9,578,474 Adicet Bio common shares outstanding, after giving effect to a one‑for‑sixteen reverse stock split effective December 30, 2025. The reporting persons certify that the securities are not held for the purpose of changing or influencing control of Adicet Bio.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Adicet Bio (ACET) does Tang Capital report?
Which Tang Capital entities are included in the Adicet Bio (ACET) Schedule 13G/A?
Does Tang Capital seek control of Adicet Bio (ACET) with this stake?
What is the significance of Item 5 in this Adicet Bio (ACET) Schedule 13G/A?
What is the event date for Tang Capital’s Adicet Bio (ACET) holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.